Yıl: 2019 Cilt: 32 Sayı: 1 Sayfa Aralığı: 27 - 32 Metin Dili: İngilizce DOI: 10.5472/marumj.518821 İndeks Tarihi: 23-03-2021

Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats

Öz:
Objective: Algan hemostatic agent (AHA) is a plant-based hemostatic agent produced in Turkey. Although, there is a great improvement in the hemostatic technologies, more effective hemostatic products are required to be produced. The aim of this study was to demonstrate the efficacy of AHA in a partial splenectomy model in rats. In addition, in this model, postoperative abdominal adhesion was evaluated.Materials and Methods: In this study 5-7 weeks old 64 rats were used. Rats were randomly divided into 8 groups, each consisting of eight rats (4 groups heparinized and 4 groups non-heparinized). Experimental splenectomy was performed and the gauze impregnated with saline was applied to the control group for the hemorrhage control, the gauze impregnated with liquid AHA, gel and powder form of AHA, was applied to the experimental groups.Results: The time to reach complete homeostasis was significantly shorter in all AHA groups compared to the control group. The powder and the gel forms of AHA stopped the bleeding in heparinized and non-heparinized groups in 1 second. The AHA fluid (sponge) form stopped the bleeding in the first application in the control group less than 10 seconds and the second time application was not necessary. The bleeding was able to be controlled in the heparinized control group (saline impregnated sponge) by 55 seconds and in the non-heparinized control group by 38 seconds.Conclusion: This study showed that AHA is a highly effective hemostatic agent, which would be beneficial in controlling hemorrhage.
Anahtar Kelime:

Deneysel parsiyel splenektomi modelinde sıçanlarda algan hemostatik ajanın kanama kontrolünde etkinliğinin araştırılması

Öz:
Amaç: Algan hemostatik ajan (AHA), Türkiye’de üretilen bitki bazlı hemostatik bir maddedir. Hemostatik teknolojilerdeki büyük gelişmelere rağmen, kanamanın kontrolünde kullanılmak üzere daha etkili hemostatik ürünlerin üretilmesi gerekmektedir. Bu çalışmanın amacı, AHA’nın sıçanlarda parsiyel splenektomi modelindeki etkinliğini göstermektir. Ayrıca bu modelde batın yapışıklığı değerlendirilmiştir. Gereçler ve Yöntemler: Bu çalışmada 5-7 haftalık 64 sıçan kullanıldı. Sıçanların her biri sekiz sıçandan oluşan 8 gruba ayrıldı (heparinize edilmiş 4 grup ve heparinize edilmemiş 4 grup). Deneysel splenektomi yapıldı ve kontrol grubuna hemoraji kontrolü için serum fizyolojik emdirilmiş gazlı bez uygulandı, deney gruplarına AHA sıvı emdirilmiş gazlı bez, jel ve toz formu uygulandı. Bulgular: Komple hemostaza ulaşma süresi, tüm AHA gruplarında kontrol grubuna kıyasla anlamlı olarak daha kısa idi. AHA’nın toz ve jel formları heparinize ve heparinize olmayan gruplarda 1 saniyede kanamayı durdurdu. AHA sıvı (sünger) formu, kontrol grubunda ilk uygulamada tüm sıçanlarda kanamayı durdurdu (10 saniyenin altında). Kanama, heparinize edilmiş kontrol grubunda (serum fizyolojik emdirilmiş gazlı bez) ortalama 55 saniyede ve heparinize olmayan kontrol grubunda 38 saniyede kontrol edilebildi. Sonuç: Bu çalışma, AHA’nın hemorajinin kontrol edilmesinde yararlı olabilecek oldukça etkili bir hemostatik ajan olduğunu göstermiştir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Uranus S, Mischinger HJ, Pfeifer J, et al. Hemostatic methods for the management of spleen and liver injuries. World J Surg 1996;20:1107-11. doi: 10.1007/s002689900.
  • 2. Davies DA, Pearl RH, Ein SH, Langer JC, Wales PW. Management of blunt splenic injury in children: Evolution of the nonoperative approach. J Pediatr Surg 2009;44:1005-8. doi: 10.1016/j.jpedsurg.2009.01.024. 3. Kuzu A, Aydıntuğ S, Karayalçın K, Köksoy C, Yerdel M A, Eraslan S. Use of autologous fibrin glue in the treatment of splenic trauma: an experimental study. Journal of Royal College of Surgeons Edinburgh 1992;37:162-4.
  • 4. King H, Shumacker HB Jr. Splenic studies: Susceptibility to infection after splenectomy performed inwiancy. Ann Surg 1952;136: 239-42.
  • 5. Schwartz M, Madariaga J, Hirose R, et al. Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg 2004;139:1148-54. doi:10.1001/ archsurg.139.11.1148
  • 6. Hanks JB, Kjaergaard HK, Hollingsbee DA. A comparison of the haemostatic effect of Vivostat patient-derived fibrin sealant with oxidised cellulose (Surgicel) in multiple surgical procedures. Eur Surg Res 2003;35:439-44. doi: 10.1159/000072229
  • 7. Ersoy G, Kaynak MF, Yilmaz O, Rodoplu U, Maltepe F, Gokmen N. Hemostatic effects of microporous polysaccharide hemosphere in a rat model with severe femoral artery bleeding. Adv Ther 2007;24:485-92. doi: 10.1007/BF02848770.
  • 8. Ward KR, Tiba MH, Holbert WH, et al. Comparison of a new hemostatic agent to current combat hemostatic agents in a swine model of lethal extremity arterial hemorrhage. J Trauma 2007;63:276-83. doi: 10.1097/TA.0b013e3180eea8a5
  • 9. Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Altern Med Rev 2010;15:329-36.
  • 10. Uçar Albayrak C, Caliskan U, Haznedaroglu IC, Goker H. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. J Int Med Res 2008;36:1447-8.doi: 10.1177/147.323.000803600121.
  • 11. Köse R, Sogut Ö, Demir T, Koruk İ. Hemostatic efficacy of folkloric medicinal plant extract in a rat skin bleeding model. Dermatol Surg 2012;38, 760-6. doi: 10.1111/j.1524-4725.2011.02288.x
  • 12. Yavuz E, Kalayci M U, Kesici S, Kesici U, Ozkara S, Yalcin O. Efficacy of ankaferd blood stopper in bleeding control in experimental partial splenectomy model. Kafkas Universitesi Veteriner Fakultesi Dergisi 2012;18: 753-8. doi:10.9775/ kvfd.2012.6324
  • 13. Midi A, Kumandaş A, Ekici H, et al. Investigation of the effectiveness of algan hemostatic agent in renal venous bleeding model in rats. EJMI 2018; 2: 129-32. doi: 10.14744/ ejmi.2018.32032.
  • 14. Midi A, Ozyurek H E, Karahan S, et al. Investigation of efficacy of the plant based algan hemostatic agent in hepatectomy bleeding model in rats. EJMI 2018; 2: 195-201 | doi: 10.14744/ejmi.2018.35744.
  • 15. Schwaitzberg SD, Chan MW, Cole DJ, et al. Comparison of poly-N-acetyl glucosamine with commercially available topical hemostats for achieving hemostasis in coagulopathic models of splenic hemorrhage. J Trauma 2004;57:S29-32. doi: 10.1097/01.TA.000.013.6747.35311.60.
  • 16. Chan MW, Schwaitzberg SD, Demcheva M, Vournakis J, Finkielsztein S, Connolly RJ. Comparison of poly-N-acetyl glucosamine (P-GlcNAc) with absorbable collagen (Actifoam), and fibrin sealant (Bolheal) for achieving hemostasis in a swine model of splenic hemorrhage. J Trauma 2000;48:454-8.
  • 17. Holcomb JB, McClain JM, Pusateri AE, et al. Fibrin sealant foam sprayed directly on liver injuries decreases blood loss in resuscitated rats. J Trauma 2000;49:246–50. 18. Tekin MI, Peşkircioğlu L, Boyvat F, et al. Practical approach to terminate urinary extravasation: percutaneous fistula tract embolization with n butyl cyanoacrylate in a case with partial nephrectomy. Tech Urol 2000;7:67-9.
  • 19. Grummet JP, Costello AJ, Swanson LC, et al. Vesicourethral anastomosis with 2-octyl cyanoacrylate adhesive in an in vivo canine model. Urology 2001;60:935-8. doi:10.1016/ S0090-4295(02)01887-3.
  • 20. Berrevoet F, de Hemptinne B. Clinical application of topical sealants in liver surgery: does it work?. Acta Chirurgica Belgica 2007;107:504-7. doi: 10.1080/00015.458.2007.116 80111.
  • 21. Yucel M O, Polat H, Bagcioglu M, et al. Comparison of the efficacy and histopathological effects of three hemostatic agents in a partial nephrectomy rat model. Int Urol Nephrol 2016; 48:65-71. doi:10.1007/s11255.015.1129-3.
  • 22. Taşkın A K, Yaşar M, Özaydın İ, et al. The hemostatic effect of calcium alginate in experimental splenic injury model. Ulus Travma Acil Cerrahi Derg 2013;19:195-99. doi: 10.5505/tjtes.2013.30676.
  • 23. Aarons CB, Cohen P A, Gower A, et al. Statins (HMG-CoA Reductase Inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann Surg 2007; 245:176-84.
  • 24. Bae JS, Ahn S J, Yim H, et al. Prevention of intraperitoneal adhesions and abscesses by polysaccharides isolated from phellinus spp in a rat peritonitis model. Ann Surg 2005; 241: 534-40.
  • 25. Galili Y, Ben-Abraham R, Rabau M, et al. Reduction of surgery-induced peritoneal adhesions by methylene blue. Am J Surg 1998;175:30-2.
  • 26. Gomez NA, Iniguez SA, Leon C J. Use of oxidized regenerated cellulose (TC7) to prevent postoperative adhesions in laparoscopic surgery. Surg Endosc 1994; 8:934.
  • 27. Cömert M, Karakaya K, Barut F, et al. Does intraabdominal use of Ankaferd Blood Stopper cause increased intraperitoneal adhesions? Ulus Travma Acil Cerrahi Derg 2010; 16:383-9.
APA Midi A, EKİCİ H, KUMANDAŞ A, DURMUŞ Ö, BODİÇ B, TİRYAKİ M, balık m, YEŞİLADA E (2019). Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats. , 27 - 32. 10.5472/marumj.518821
Chicago Midi Ahmet,EKİCİ Hüsamettin,KUMANDAŞ ALİ,DURMUŞ Ömercan,BODİÇ Buse,TİRYAKİ Mehmet Zahit,balık mehmet sabri,YEŞİLADA Erdem Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats. (2019): 27 - 32. 10.5472/marumj.518821
MLA Midi Ahmet,EKİCİ Hüsamettin,KUMANDAŞ ALİ,DURMUŞ Ömercan,BODİÇ Buse,TİRYAKİ Mehmet Zahit,balık mehmet sabri,YEŞİLADA Erdem Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats. , 2019, ss.27 - 32. 10.5472/marumj.518821
AMA Midi A,EKİCİ H,KUMANDAŞ A,DURMUŞ Ö,BODİÇ B,TİRYAKİ M,balık m,YEŞİLADA E Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats. . 2019; 27 - 32. 10.5472/marumj.518821
Vancouver Midi A,EKİCİ H,KUMANDAŞ A,DURMUŞ Ö,BODİÇ B,TİRYAKİ M,balık m,YEŞİLADA E Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats. . 2019; 27 - 32. 10.5472/marumj.518821
IEEE Midi A,EKİCİ H,KUMANDAŞ A,DURMUŞ Ö,BODİÇ B,TİRYAKİ M,balık m,YEŞİLADA E "Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats." , ss.27 - 32, 2019. 10.5472/marumj.518821
ISNAD Midi, Ahmet vd. "Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats". (2019), 27-32. https://doi.org/10.5472/marumj.518821
APA Midi A, EKİCİ H, KUMANDAŞ A, DURMUŞ Ö, BODİÇ B, TİRYAKİ M, balık m, YEŞİLADA E (2019). Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats. Marmara Medical Journal, 32(1), 27 - 32. 10.5472/marumj.518821
Chicago Midi Ahmet,EKİCİ Hüsamettin,KUMANDAŞ ALİ,DURMUŞ Ömercan,BODİÇ Buse,TİRYAKİ Mehmet Zahit,balık mehmet sabri,YEŞİLADA Erdem Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats. Marmara Medical Journal 32, no.1 (2019): 27 - 32. 10.5472/marumj.518821
MLA Midi Ahmet,EKİCİ Hüsamettin,KUMANDAŞ ALİ,DURMUŞ Ömercan,BODİÇ Buse,TİRYAKİ Mehmet Zahit,balık mehmet sabri,YEŞİLADA Erdem Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats. Marmara Medical Journal, vol.32, no.1, 2019, ss.27 - 32. 10.5472/marumj.518821
AMA Midi A,EKİCİ H,KUMANDAŞ A,DURMUŞ Ö,BODİÇ B,TİRYAKİ M,balık m,YEŞİLADA E Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats. Marmara Medical Journal. 2019; 32(1): 27 - 32. 10.5472/marumj.518821
Vancouver Midi A,EKİCİ H,KUMANDAŞ A,DURMUŞ Ö,BODİÇ B,TİRYAKİ M,balık m,YEŞİLADA E Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats. Marmara Medical Journal. 2019; 32(1): 27 - 32. 10.5472/marumj.518821
IEEE Midi A,EKİCİ H,KUMANDAŞ A,DURMUŞ Ö,BODİÇ B,TİRYAKİ M,balık m,YEŞİLADA E "Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats." Marmara Medical Journal, 32, ss.27 - 32, 2019. 10.5472/marumj.518821
ISNAD Midi, Ahmet vd. "Investigation of the effectiveness of algan hemostatic agent in bleeding control using an experimental partial splenectomy model in rats". Marmara Medical Journal 32/1 (2019), 27-32. https://doi.org/10.5472/marumj.518821